Chaithra S K: A “Low-Cost IVF” Ad in India Usually Isn’t Lying
Chaithra S K, Medical Director at Ovum Fertility, shared on LinkedIn:
“A ‘low-cost IVF’ ad in India usually isn’t lying.
It’s just not showing the whole bill.
Here’s what’s actually happening:
The advertised figure – often pitched around ₹1 lakh – is typically just the base cycle fee.
Medications, monitoring, and embryology charges are frequently priced separately.
Add-ons like:
- PGT-A,
- embryo glue,
- and immune infusions
get introduced after the first consultation, once a patient is already invested.
By the time a cycle is complete, real spend often lands closer to ₹2.5-3 lakh
Not a single commonly marketed add-on currently carries a ‘proven to help’ rating from the world’s most established independent review system.
A study published this year assessed ten of the most heavily marketed add-ons – seven showed no measurable effect on outcomes, or evidence too weak to support the claims made for them.
And here’s the layer that’s specific to India:
The ART (Regulation) Act, 2021 governs clinic registration, gamete screening, and consent.
What it doesn’t include is an independent body rating add-on evidence – the way some other markets now require
So a patient here is paying the full cost herself, with less institutional visibility into what’s actually backed by evidence than patients in markets that do have a rating system.
In other words: the ad isn’t the lie. The silence between the ad and the invoice is.
So the real question for a clinic isn’t ‘what’s our starting price?’
It’s ‘does our final bill match the number a patient walked in expecting?’
Here’s what that mismatch costs, beyond one bad review:
India’s IVF market runs almost entirely out of pocket.
A patient who overspends on unproven extras in cycle one often has less room for cycle two – the one that, statistically, may have mattered more.
That’s not just a pricing problem. That’s a patient a clinic won’t get to treat twice.
The clinics that win India’s IVF market over the next few years won’t be the cheapest line on the ad.
They’ll be the ones whose final invoice looks like the first number they quoted.”
Stay informed with the latest updates in fertility and reproductive medicine on Fertility News.
-
Oct 16, 2026, 19:56Dina Ibrahem: Poor ICM vs. Poor TE
-
Oct 16, 2026, 19:47Sean Lauber: NIPT and Amniocentesis after PGT-A Reveal Few Abnormalities
-
Oct 16, 2026, 19:42Devyanshi Dixit: C-Section vs. Vaginal Birth – 2 Birth Paths, 2 Very Different Recoveries
-
Oct 16, 2026, 19:32Pawel Kordowitzki: Maternal Vitamin D Homeostasis, Pregnancy Outcomes and Offspring Health
-
Oct 16, 2026, 19:13Shizuko Takahashi: Our Study on Women’s Experiences of Assisted Reproductive Care in China Has Been Accepted by RBMO
-
Oct 16, 2026, 19:09ESHRE Announces ECRES-GESEA Reproductive Surgery Training and Certification in Slovenia
-
Oct 16, 2026, 18:20Kabita KB: What Happens if PLCZ1 Is Defective?
-
Oct 16, 2026, 18:12Partha Sarathi Das: From Reproductive Lifespan to Reproductive Healthspan
-
Oct 16, 2026, 18:05Joyce Harper: It Was a Pleasure to Give 2 Talks Celebrating World Menopause Day